Aduriz-Lorenzo PM, Aduriz-Llaneza P, Araiz-Iribarren J, Khamashta MA. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? Lupus. 2020;29(7):671–5.
Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmol. 2003;110(7):1321–6.
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.
Couturier A, Giocanti-Aurégan A, Dupas B, Girmens JF, Le Mer Y, Massamba N, et al. Update on recommendations for screening for hydroxychloroquine retinopathy. J Fr Ophtalmol. 2017;40(9):793–800.
Article CAS PubMed Google Scholar
Alieldin RA, Boonarpha N, Saedon H. Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years’ audit. Eye. 2022;2022(28):1–6.
Browning DJ, Lee C. Relative sensitivity and specificity of 10–2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol. 2014;25(8):1389–99.
Muller R. Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. Rheumatol Int. 2021;41(7):1189–202.
Article CAS PubMed PubMed Central Google Scholar
Pandya HK, Robinson M, Mandal N, Shah VA. Hydroxychloroquine retinopathy: A review of imaging. Indian J Ophthalmol. 2015;63(7):570.
Article PubMed PubMed Central Google Scholar
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF, Lum F. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmol. 2016;123(6):1386–94.
Agarwal A, Karkhur S, Aggarwal K, Invernizzi A, Singh R, Dogra MR, et al. Epidemiology and clinical features of inflammatory retinal vascular occlusions: pooled data from two tertiary-referral institutions. Clin Experiment Ophthalmol. 2018;46(1):62–74.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2019;71(9):1400.
Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). http://dx.doi.org/https://doi.org/10.1080/1474033820171269168. 2016;16(3):411–9.
Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J. 2001;24(5):329–34.
Wang G, Zhuo N, Liao Z, Qi W, Tian F, Wen Z, et al. Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report. Medicine (Baltimore). 2021;100(22): e25688.
Warner AE. Early Hydroxychloroquine Macular Toxicity. Arthritis Rheum. 2001;44(8):1959–61.
Article CAS PubMed Google Scholar
Cerri E, Origlia N, Falsini B, Barloscio D, Fabiani C, Sansò M, et al. Conjunctivally Applied BDNF Protects Photoreceptors from Light-Induced Damage. Transl Vis Sci Technol. 2015;4(6):1. https://doi.org/10.1167/tvst.4.6.1.
Azadi S, Johnson LE, Paquet-Durand F, Perez MTR, Zhang Y, Ekström PAR, et al. CNTF+BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res. 2007;1129(1):116–29.
Article CAS PubMed Google Scholar
Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res. 2012;31(2):136–51.
Article CAS PubMed Google Scholar
Baranov P, Lin H, McCabe K, Gale D, Cai S, Lieppman B, et al. A Novel Neuroprotective Small Molecule for Glial Cell Derived Neurotrophic Factor Induction and Photoreceptor Rescue. J Ocul Pharmacol Ther. 2017;33(5):412–22.
留言 (0)